SlowMist: EIP-7702 account vulnerability exploited, 1,988.5 QNT stolen
ChainCatcher news, according to market sources, an attacker exploited a flawed EIP-7702 account to steal 1,988.5 QNT (equivalent to approximately 54.93 ETH) from the QNT reserve pool. The root cause was that the reserve pool manager EOA delegated code via EIP-7702 to the BatchExecutor contract, which in turn authorized the BatchCall contract without proper access control.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Samsung’s earnings report far exceeds expectations, South Korean stocks rebound strongly by over 5%, Samsung rises more than 5%, and Japanese stocks gain over 2%
Samsung Electronics’ net profit surged significantly year-on-year in the second quarter, far exceeding expectations. Additionally, the South Korean government announced measures to stabilize the market, including restricting retail investors from participating in leveraged ETFs. As a result, the KOSPI’s intraday gain on Thursday expanded to 5%. Samsung’s share price rose 5.5%, SK Hynix increased by 2%. The KOSPI has fallen around 40% from its June peak. The Nikkei 225 Index rose more than 2% during the day, with Kioxia surging over 12%.
Samsung’s above-expectation performance and government intervention to limit leveraged ETFs turn South Korea’s stock market from losses to gains
Samsung Electronics reported a more than 250-fold year-on-year surge in second-quarter net profit. Additionally, the government's announcement of new measures to further restrict retail participation in leveraged ETFs boosted market sentiment in South Korea.

Johnson & Johnson (JNJ.US) Continues to Advance Innovative Therapies: Partners with Sail to Develop In Vivo CAR-T and Secures $2.58 Billion Acquisition Option, Completes Acquisition of Firefly Bio
Johnson & Johnson (JNJ.US) has disclosed two initiatives in cutting-edge biomedicine development.

